The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials
Open accessAbstract
Objective: Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at increased risk of respiratory infection. The aim of this study was to evaluate the relative risk (RR) of pulmonary disease among patients with RA treated with methotrexate. Methods: We searched the PubMed and Cochrane databases (publication dates January 1, 1990 to February 1, 2013) for double‐blind, randomized, controlled trials of methotrexate versus placebo or active comparator agents in adults with RA. Studies with <100 subjects or with a duration of <24 weeks were excluded. Two investigators independently searched both databases, and all of the investigators reviewed the selected studies. We compared differences in the RR using the Mantel‐Haenszel random‐effects method. Results: A total of 22 studies with 8,584 participants met the inclusion criteria. Heterogeneity across studies was not significant (I 2 = 3%), allowing combination of the trial results. Methotrexate was associated with an increased risk of all adverse respiratory events (RR 1.10, 95% confidence interval [95% CI] 1.02−1.19) and respiratory infection (RR 1.11, 95% CI 1.02−1.21). Patients treated with methotrexate were not at increased risk of death due to lung disease (RR 1.53, 95% CI 0.46−5.01) or noninfectious respiratory events (RR 1.02, 95% CI 0.65−1.60). A subgroup analysis of studies in which pneumonitis was described revealed an increased risk associated with methotrexate (RR 7.81, 95% CI 1.76−34.72). Conclusion: Our study demonstrated a small but significant increase in the risk of lung disease in patients with RA treated with methotrexate compared with other disease‐modifying antirheumatic drugs and biologic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review
Wang, W., Zhou, H., & Liu, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.027 · Cited by 562
Drug-Induced Interstitial Lung Disease: A Systematic Review
Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100356 · Cited by 422
Rheumatoid arthritis-associated lung disease
Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015) · European Respiratory Review · doi:10.1183/09059180.00008014 · Cited by 366
Kadura, S., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0011-2021 · Cited by 328
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease
Spagnolo, P., Lee, J. S., Sverzellati, N., Rossi, G., & Cottin, V. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40574 · Cited by 306
Metadata
- Authors
- Conway, R., Low, C., Coughlan, R. J., O'Donnell, M. J., & Carey, J. J.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-03-28
- Volume
- 66
- Issue
- 4
- Pages
- 803-812
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W1737953065
- Cited by
- 249
- References
- 1
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1002/art.38322
- The paper
- Conway, R., Low, C., Coughlan, R. J., O'Donnell, M. J., & Carey, J. J. (2014). Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials. Arthritis & Rheumatology. https://doi.org/10.1002/art.38322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.